GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Plans » Clover Health Investments Corp (NAS:CLOV) » Definitions » Peter Lynch Fair Value

Clover Health Investments (Clover Health Investments) Peter Lynch Fair Value : N/A (As of May. 26, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Clover Health Investments Peter Lynch Fair Value?

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.


The historical rank and industry rank for Clover Health Investments's Peter Lynch Fair Value or its related term are showing as below:



CLOV's Price-to-Peter-Lynch-Fair-Value is not ranked *
in the Healthcare Plans industry.
Industry Median: 1.55
* Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.

Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.


Clover Health Investments Peter Lynch Fair Value Historical Data

The historical data trend for Clover Health Investments's Peter Lynch Fair Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clover Health Investments Peter Lynch Fair Value Chart

Clover Health Investments Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Peter Lynch Fair Value
- - - - -

Clover Health Investments Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Peter Lynch Fair Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Clover Health Investments's Peter Lynch Fair Value

For the Healthcare Plans subindustry, Clover Health Investments's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clover Health Investments's Price-to-Peter-Lynch-Fair-Value Distribution in the Healthcare Plans Industry

For the Healthcare Plans industry and Healthcare sector, Clover Health Investments's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:

* The bar in red indicates where Clover Health Investments's Price-to-Peter-Lynch-Fair-Value falls into.



Clover Health Investments Peter Lynch Fair Value Calculation

Clover Health Investments's Peter Lynch Fair Value for today is calculated as

Peter Lynch Fair Value=PEG Ratio*5-Year TTM EBITDA Growth Rate***EPS without NRI (TTM)
=1* N/A *-0.376
=N/A

Clover Health Investments's EPS without NRI for the trailing twelve months (TTM) uses the latest annual data, which was $-0.38.

* Note that for companies that do not have enough quarterly data to calculate the 5-Year TTM EBITDA Growth Rate, we use the annual data for the calculation.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.

If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.

If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.


Clover Health Investments  (NAS:CLOV) Peter Lynch Fair Value Explanation

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.

Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.

Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 0 instead of 15 in this case.

Clover Health Investments's Price to Peter Lynch Fair Value Ratio for today is calculated as

Price to Peter Lynch Fair Value=Share Price/Peter Lynch Fair Value
=1.00/N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Clover Health Investments Peter Lynch Fair Value Related Terms

Thank you for viewing the detailed overview of Clover Health Investments's Peter Lynch Fair Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Clover Health Investments (Clover Health Investments) Business Description

Traded in Other Exchanges
Address
3401 Mallory Lane, Suite 210, Franklin, TN, USA, 37067
Clover Health Investments Corp is a healthcare technology company. It uses its proprietary technology platform to collect, structure, & analyze health & behavioral data to improve medical outcomes & lower costs for patients. The Group has two operating segments. The insurance segment provides PPO(Preferred provider Organization) & HMO(Health Maintenance Organization) plans to Medicare Advantage members in several states & seeks to improve care & lower costs which generally provide access to a wide network of primary care providers, specialists, & hospitals. Non-insurance segment includes the Company's operations relating to CMS' DC (Direct Contracting) Model, which provides options aimed at reducing expenditures & preserving or enhancing the quality of care for beneficiaries.
Executives
Karen Soares officer: General Counsel & Secretary 3401 MALLORY LANE, SUITE 210, FRANKLIN TN 37067
Clover Health Investments, Corp. /de officer: Chief Technology Officer 3401 MALLORY LANE, SUITE 210, FRANKLIN TN 37067
Anna U Loengard director C/O CLOVER HEALTH INVESTMENTS, CORP., 3401 MALLORY LANE, SUITE 210, FRANKLIN TN 37067
Andrew Toy director, officer: Chief Executive Officer C/O CLOVER HEALTH INVESTMENTS, CORP., 725 COOL SPRINGS BLVD., SUITE 320, FRANKLIN TN 37067
Scott J. Leffler officer: Chief Financial Officer C/O CLOVER HEALTH INVESTMENTS, CORP., 3401 MALLORY LANE, SUITE 210, FRANKLIN TN 37067
Brady Patrick Priest officer: CEO of Home Care C/O CLOVER HEALTH INVESTMENTS, CORP., FRANKLIN TN 37067
Demetrios L. Kouzoukas director C/O CLOVER HEALTH INVESTMENTS, CORP., 725 COOL SPRINGS BLVD., SUITE 320, FRANKLIN FL 37067
Aric R Sharp officer: CEO of Value-Based Care C/O CLOVER HEALTH INVESTMENTS, CORP., 3401 MALLORY LANE, SUITE 210, FRANKLIN TN 37067
Wai Conrad officer: Chief Technology Officer 3401 MALLORY LANE, SUITE 210, FRANKLIN TN 37067
Joseph Richards Martin officer: General Counsel C/O LOUISIANA-PACIFIC CORPORATION, 414 UNION STREET, SUITE 2000, NASHVILLE TN 37219
Vivek Garipalli director, 10 percent owner, officer: Executive Chairperson C/O CLOVER HEALTH INVESTMENTS, CORP., 725 COOL SPRINGS BLVD., SUITE 320, FRANKLIN TN 37067
Carladenise Armbrister Edwards director C/O CLOVER HEALTH INVESTMENTS, CORP., 3401 MALLORY LANE, SUITE 210, FRANKLIN TN 37067
Chelsea Clinton director C/O IAC 555 W 18TH STREET, NEW YORK NY 10011
Jamie L. Reynoso officer: CEO of Medicare Advantage C/O CLOVER HEALTH INVESTMENTS, CORP., 725 COOL SPRINGS BLVD., SUITE 320, FRANKLIN TN 37067
Chamath Palihapitiya 10 percent owner, other: See Remarks THE SOCIAL-CAPITAL PARTNERSHIP, L.L.C., 506 SANTA CRUZ AVENUE, SUITE 300, MENLO PARK CA 94025

Clover Health Investments (Clover Health Investments) Headlines